Charlotte Seyon Marcus, MD
Gynecologic Oncology
Accepting new patients
Sees patients age 18 and up
Penn Gynecologic Oncology Bucks County
View 1 additional location
Make an appointmentCall 800-789-7366
Penn Medicine Provider

About me

  • Adjunct Assistant Professor of Obstetrics and Gynecology

Education and training

  • Medical School: New York University School of Medicine
  • Residency: NYU Langone/Bellevue Hospital Center
  • Residency: George Washington University Medical Center
  • Fellowship: National Cancer Institute

What my patients think about me

Average Rating

285 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

November 2025
she is the best!
November 2025
excellent manner and professional
October 2025
she is kind, easy to talk to, listens and explains everything well
October 2025
dr. marcus is an amazing physician, immensely skilled and incredibly supportive.

Insurance accepted

My Locations

Penn Gynecologic Oncology Bucks County

Penn Medicine hospital privileges

  • Princeton Medical Center: Has privileges to treat patients in the hospital.
Dr. Marcus is a Penn Medicine physician. In New Jersey, providers are affiliated with Penn Medicine through Clinical Health Care Associates of New Jersey or Princeton Healthcare Affiliated Physicians, PC.

Qualifications and experience

Treatments and Conditions

My research

Penick ER, Hamilton CA, Maxwell GL, Marcus CS Germ cell, stromal, and other ovarian tumors. , Clinical Gynecologic Oncology, 9th ed. Elsevier, 12:290-313: 2018

Braverman JA, Marcus C, Garg R Anti-NMDA-receptor encephalitis: A neuropsychiatric syndrome associated with ovarian teratoma. , Gynecol Oncol Rep, 14:1-3: 2015

Bateman NW, Jaworski E, Ao W, Wang G, Litzi T, Dubil E, Marcus C, Conrads KA, Teng PN, Hood BL, Phippen NT, Vasicek LA, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Darcy KM, Conrads TP Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. , J Proteome Res, 14(4):1900-10: 2015

Marcus, CS, Conrads KA, Teng PN, Dubil EA, Maxwell GL, Hamilton CA, Conrads TP. Pharmacologic inhibition of polo-like kinase 1 enhances paclitaxel-based cell killing in taxol resistant ovarian cancer cells. Poster presentation. , 45th Annual Meeting on Women’s Cancer, Society of Gynecologic Oncology. : 2014

Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. , J Cancer, 5(1):25-30: 2014

Dubil EA, Marcus CS, Teng PN, Hood BL, Conrads KA, Guisong W, Maxwell GL, Hamilton CA, Conrads TP. Inhibition of ATM Kinase Sensitizes Epithelial Ovarian Cancer to Paclitaxel. Oral presentation. District Annual Meeting , ACOG Armed Forces District Annual Meeting : 2013

Risinger JI, Allard J, Chandran U, Day R, Chandramouli GV, Miller C, Zahn C, Oliver J, Litzi T, Marcus C, Dubil E, Byrd K, Cassablanca Y, Becich M, Berchuck A, Darcy KM, Hamilton CA, Conrads TP, Maxwell GL Gene expression analysis of early stage endometrial cancers reveals unique transcripts associated with grade and histology but not depth of invasion. , Front Oncol, 3:139: 2013

Marcus CS, Lepor, H. The factors predicting positive surgical margins after open radical retropubic prostatectomy. Poster presentation. , American Urological Association Annual Meeting. : 2005